“Advancements in Monoclonal Antibodies & Targeted Biologics for AIHA Management”
- One prominent trend in AIHA treatment is the increasing development and use of monoclonal antibodies (e.g., rituximab, sutimlimab) and complement inhibitors that target specific pathways of red blood cell destruction.
- These biologics offer greater efficacy and fewer side effects compared to traditional immunosuppressants, especially in patients with refractory or relapsed AIHA.
- For instance, newly developed complement inhibitors block the classical complement pathway, providing targeted treatment with promising clinical trial results in cold agglutinin disease (CAD), a subtype of AIHA.
- The rise of personalized medicine and precision immunotherapy is reshaping the AIHA treatment paradigm, allowing hematologists to tailor therapies based on patient-specific biomarkers.
- These innovations are transforming chronic autoimmune disease management, leading to better remission rates, fewer relapses, and improved quality of life for patients
